PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine kinase …

PURPOSE The regimens approved for the treatment of advanced head and neck squamous
cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income …

Lung cancer is one of the leading causes of cancer-related deaths. Accurate assessment of
disease extent is important in deciding the optimal treatment approach. To play an important …

Background Grade ≥2 acute xerostomia between 3D conformal radiotherapy (RT) and
intensity‐modulated radiotherapy (IMRT) was evaluated in patients with head and neck …

Background Because the addition of nimotuzumab to chemoradiation in patients with locally
advanced head and neck cancer improved outcomes in a phase 2 study, the authors …

PURPOSE There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible
patients with locally advanced head and neck squamous cell carcinoma (…

Screening for EGFR mutation is a key molecular test for management of lung cancer patients.
Outcome of patients with mutation receiving EGFR tyrosine kinase inhibitor is known to be …

Purpose Locally advanced (T3/T4) gallbladder cancers with large fixed portal nodes have a
dismal prognosis. If undertaken, surgery entails extensive resections with high morbidity; …

Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free
survival (PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …

Metaiodobenzylguanidine, a guanithidine analog, labeled with 123 I and 131 I, is used for
imaging and therapy of neuroblastomas and various neural crest tumors like paragangliomas, …